In yesterday’s Wall Street session, Unicycive Therapeutics Inc. (NASDAQ:UNCY) shares traded at $1.62, up 8.00% from the previous session.
UNCY stock price is now 183.43% away from the 50-day moving average and 129.96% away from the 200-day moving average. The market capitalization of the company currently stands at $24.80M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
In other news, Schiller Brigitte, Director bought 15,000 shares of the company’s stock on May 16. The stock was bought for $12,375 at an average price of $0.82. Upon completion of the transaction, the Director now directly owns 15,000 shares in the company, valued at $24300.0. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in UNCY stock. A new stake in Unicycive Therapeutics Inc. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $23,000. In total, there are 14 active investors with 18.30% ownership of the company’s stock.
Wednesday morning saw Unicycive Therapeutics Inc. (NASDAQ: UNCY) opened at $1.4400. During the past 12 months, Unicycive Therapeutics Inc. has had a low of $0.40 and a high of $2.16. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.80, and a quick ratio of 1.80. The fifty day moving average price for UNCY is $0.5716 and a two-hundred day moving average price translates $0.7045 for the stock.
The latest earnings results from Unicycive Therapeutics Inc. (NASDAQ: UNCY) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.37, missing analysts’ expectations of -$0.28 by -0.09. This compares to -$0.37 EPS in the same period last year.
Unicycive Therapeutics Inc.(UNCY) Company Profile
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Leave a Reply